WEED vs. CMED, EMC, OGI, ICC, LEAF, MGW, BE, BLO, SL, and MJN
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include CanniMed Therapeutics (CMED), Emblem (EMC), Organigram (OGI), ICC Labs (ICC), Leaf Mobile (LEAF), Maple Leaf Green World (MGW), Beleave (BE), Cannabix Technologies (BLO), Supreme Cannabis Company Inc, (SL), and Cronos Group (MJN). These companies are all part of the "cannabis" industry.
Canopy Growth vs.
Canopy Growth (TSE:WEED) and CanniMed Therapeutics (TSE:CMED) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, community ranking, earnings, risk and institutional ownership.
CanniMed Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -201.27%. CanniMed Therapeutics' return on equity of 0.00% beat Canopy Growth's return on equity.
9.4% of Canopy Growth shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Canopy Growth had 8 more articles in the media than CanniMed Therapeutics. MarketBeat recorded 8 mentions for Canopy Growth and 0 mentions for CanniMed Therapeutics. Canopy Growth's average media sentiment score of 1.31 beat CanniMed Therapeutics' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media.
CanniMed Therapeutics has lower revenue, but higher earnings than Canopy Growth.
Canopy Growth currently has a consensus target price of C$5.64, suggesting a potential upside of 129.20%. Given Canopy Growth's stronger consensus rating and higher probable upside, equities research analysts plainly believe Canopy Growth is more favorable than CanniMed Therapeutics.
Canopy Growth received 483 more outperform votes than CanniMed Therapeutics when rated by MarketBeat users. However, 75.85% of users gave CanniMed Therapeutics an outperform vote while only 61.96% of users gave Canopy Growth an outperform vote.
Summary
Canopy Growth beats CanniMed Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Canopy Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for WEED and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
Related Companies and Tools
This page (TSE:WEED) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy WEED Stock Free WEED Stock Alerts